Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Acute Myeloid Leukaemia: Update Bulletin [November 2017]

Product Code:
596200743
Publication Date:
November 2017
Format:
PDF
Price:
£910

This edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on the FDA approval of Celgene and Agios Pharmaceuticals’ Idhifa (enasidenib), a first-in-class targeted therapy for the treatment of relapsing or refractory AML patients with an isocitrate dehydrogenase-2 (IDH2) mutation. KOLs also provide their insights on the FDA approval of Jazz Pharmaceuticals’ novel liposomal chemotherapy agent Vyxeos (CPX-351), which is indicated for two populations of patients with high-risk AML. Roche and AbbVie’sVenclexta/Venclyxto (venetoclax) which has recently progressed to Phase III evaluation in AML is also discussed.

Business Questions:

• How do KOLs perceive the launch of Idhifa and how strong is the supporting data?
• What is the anticipated size of the patient pool for Idhifa given that it is indicated for adults with relapsing or refractory AML who harbour an IDH2 mutation?
• What barriers, if any, exist to the uptake of Idhifa as a treatment for AML?
• Now that Idhifa has been approved, how do opinion leaders view the potential of IDH1 inhibitors (which are earlier in the development pipeline) for AML?
• How do the opinion leaders perceive the supporting Phase III data for Vyxeos’ approval in AML?
• What benefits does Vyxeos offer over established standard of care therapies?
• How will Vyxeos fair in the current market and what barriers might impact uptake amongst AML patients?
• How do KOLs view Venclexta/Venclyxto’s potential as a treatment for AML?
• How do opinion leaders view the two Phase III studies investigating venetoclax in combination with low-dose cytarabine (LDAC) or azacitidine and what are the differentiating factors?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved